CN104147019B - 闭花木酮的o-(四氢吡咯基)乙基衍生物在制备预防或治疗胰腺纤维化药物中的应用 - Google Patents
闭花木酮的o-(四氢吡咯基)乙基衍生物在制备预防或治疗胰腺纤维化药物中的应用 Download PDFInfo
- Publication number
- CN104147019B CN104147019B CN201410375246.7A CN201410375246A CN104147019B CN 104147019 B CN104147019 B CN 104147019B CN 201410375246 A CN201410375246 A CN 201410375246A CN 104147019 B CN104147019 B CN 104147019B
- Authority
- CN
- China
- Prior art keywords
- cleistanone
- ethyl derivative
- nafoxidine base
- pancreatic gland
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- XURLTFUKDPZAPN-QFIPXVFZSA-N Cleistanone Natural products O(C)[C@H]1OC(=O)c2c(-c3cc4OCOc4cc3)c3c(c(O)c12)cc(OC)c(OC)c3 XURLTFUKDPZAPN-QFIPXVFZSA-N 0.000 title claims abstract description 76
- 229950002366 nafoxidine Drugs 0.000 title claims abstract description 37
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 title claims abstract description 36
- 206010016654 Fibrosis Diseases 0.000 title claims abstract description 23
- 230000004761 fibrosis Effects 0.000 title claims abstract description 23
- 210000004907 gland Anatomy 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000003814 drug Substances 0.000 title claims abstract description 13
- 230000002265 prevention Effects 0.000 title abstract description 5
- GEIFQLXIDUDMNZ-PCJVTFPHSA-N (4aR,4bR,6aR,8S,10aR,10bR,12R,12aR)-12-hydroxy-1,1,1',1',4a,10a,10b-heptamethyl-3'-methylidenespiro[3,4,4b,5,6,6a,7,9,10,11,12,12a-dodecahydrochrysene-8,2'-cyclopentane]-2-one Chemical compound CC1(C)CCC(=C)[C@@]11C[C@@H](CC[C@H]2[C@]3(C[C@@H](O)[C@H]4C(C)(C)C(=O)CC[C@@]42C)C)[C@@]3(C)CC1 GEIFQLXIDUDMNZ-PCJVTFPHSA-N 0.000 claims abstract description 64
- 210000000496 pancreas Anatomy 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 11
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 5
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 5
- 229960002591 hydroxyproline Drugs 0.000 claims description 5
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 5
- 241000785597 Cleistanthus Species 0.000 claims description 4
- 230000008595 infiltration Effects 0.000 claims description 2
- 238000001764 infiltration Methods 0.000 claims description 2
- 210000004969 inflammatory cell Anatomy 0.000 claims description 2
- 150000002576 ketones Chemical class 0.000 claims 2
- 239000002023 wood Substances 0.000 claims 2
- 238000002474 experimental method Methods 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 abstract 3
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 241001597008 Nomeidae Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000002946 anti-pancreatic effect Effects 0.000 description 5
- 208000035126 Facies Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- 0 CC(C)(C(*)(C(C1)OCC*2CCCC2)C(C)(CC2)C3(*)C1(C)C(C)(CCCC1)C1(*)CC3)C2=O Chemical compound CC(C)(C(*)(C(C1)OCC*2CCCC2)C(C)(CC2)C3(*)C1(C)C(C)(CCCC1)C1(*)CC3)C2=O 0.000 description 1
- HHVJYBCGWZUROZ-UHFFFAOYSA-N CC(C)(CC1)CC1=C Chemical compound CC(C)(CC1)CC1=C HHVJYBCGWZUROZ-UHFFFAOYSA-N 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- GGLZPLKKBSSKCX-UHFFFAOYSA-N S-ethylhomocysteine Chemical compound CCSCCC(N)C(O)=O GGLZPLKKBSSKCX-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ODJZWVFLHZHURI-UHFFFAOYSA-M [Br-].C(CCC)[P+](CCCC)(CCCC)CCCC.[NH4+].[Br-] Chemical compound [Br-].C(CCC)[P+](CCCC)(CCCC)CCCC.[NH4+].[Br-] ODJZWVFLHZHURI-UHFFFAOYSA-M 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- SISAYUDTHCIGLM-UHFFFAOYSA-N bromine dioxide Inorganic materials O=Br=O SISAYUDTHCIGLM-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 229940056582 human hair preparation Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000002705 pancreatic stellate cell Anatomy 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及有机合成和药物化学领域，具体涉及闭花木酮Cleistanone的O‑(四氢吡咯基)乙基衍生物、制备方法及其在制备预防或治疗胰腺纤维化药物上的用途。本发明合成了一个新的闭花木酮Cleistanone的O‑(四氢吡咯基)乙基衍生物，并公开了其制备方法。药理学实验表明，本发明的闭花木酮Cleistanone的O‑(四氢吡咯基)乙基衍生物具有预防或治疗胰腺纤维化的作用，具有开发预防或治疗胰腺纤维化药物的价值。
Description
技术领域
本发明涉及有机合成和药物化学领域，具体涉及闭花木酮Cleistanone的O-(四氢吡咯基)乙基衍生物、制备方法及其用途。
背景技术
胰腺纤维化是各种原因所致慢性胰腺炎的共同特征,同时也是与其伴随的组织病理学特点,表现为大量成纤维细胞增生和富含连接组织的细胞外基质。是多种原因导致胰腺损伤修复的结果，近期发现胰腺星状细胞和多种细胞因子与胰腺纤维化有关，胰腺纤维化目前发病率愈来愈高，急需研发高效低毒的抗胰腺纤维化药物。
胰腺纤维化的治疗目前已有的药物存在毒性大、安全性低的问题，从天然产物中寻找化合物或先导化合物并进行结构修饰获得其衍生物，从而得到高效低毒的潜在药物最有重要价值。
本发明涉及的化合物闭花木酮Cleistanone是一个2011年发表(Van Trinh ThiThanh et al.,2011.Cleistanone:A Triterpenoid from Cleistanthus indochinensis witha New Carbon Skeleton.Volume 2011,Issue 22,pages 4108–4111,August 2011)的化合物，我们对化合物闭花木酮Cleistanone进行了结构修饰，获得了一个新的闭花木酮Cleistanone的O-(四氢吡咯基)乙基衍生物，并对其抗胰腺纤维化活性进行了评价，其具有抗胰腺纤维化活性。
发明内容
本发明公开了一个闭花木酮Cleistanone的O-(四氢吡咯基)乙基衍生物，其结构为：
本发明闭花木酮Cleistanone的O-(四氢吡咯基)乙基衍生物(III)可通过下面方法制备：
(1)闭花木酮Cleistanone(I)与1,2-二溴乙烷反应得到闭花木酮Cleistanone的O-溴乙基衍生物(II)；
(2)闭花木酮Cleistanone的O-溴乙基衍生物(II)与吡咯烷发生取代反应制得闭花木酮Cleistanone的O-(四氢吡咯基)乙基衍生物(III)。
进一步的闭花木酮Cleistanone的O-(四氢吡咯基)乙基衍生物(III)的制备方法为：
(1)将440mg化合物闭花木酮Cleistanone(I)溶于10mL苯，向溶液中加入0.04g的四丁基溴化铵，3.760g的1,2-二溴乙烷和6mL的50％氢氧化钠溶液；混合物在25摄氏度搅拌24h；24h之后将反应液倒入冰水中，立即用二氯甲烷萃取两次，合并有机相溶液；然后对有机相溶液依次用水和饱和食盐水洗涤3次，再用无水硫酸钠干燥，最后减压浓缩去除溶剂得到产物粗品；产物粗品用硅胶柱层析纯化，流动相为：石油醚/丙酮＝100:1，v/v，收集黄色集中洗脱带即得到闭花木酮Cleistanone的O-溴乙基衍生物(II)的黄色固体。
(2)将273mg的闭花木酮Cleistanone的O-溴乙基衍生物溶于20mL乙腈当中，向其中加入345mg的无水碳酸钾，84mg的碘化钾和1420mg的吡咯烷，混合物加热回流8h；反应结束后将反应液倒入冰水中，用等量二氯甲烷萃取三次，合并有机相；依次用水和饱和食盐水洗涤合并之后的有机相，再用无水硫酸钠干燥，减压浓缩去除溶剂得到产物粗品；产物粗品用硅胶柱层析纯化，流动相为：石油醚/丙酮＝100:1，v/v，收集淡黄色集中洗脱带即得到闭花木酮Cleistanone的O-(四氢吡咯基)乙基衍生物(III)的淡黄色胶状固体。
本发明公开的化合物可以制成药学上可接受的盐或药学上可接受的载体。
药效学实验表明，本发明的闭花木酮Cleistanone的O-(四氢吡咯基)乙基衍生物(III)具有较好的抗胰腺纤维化作用。本发明的药学上可接受的盐与其化合物具有同样的药效。
以下通过实施例对本发明作进一步详细的说明，但本发明的保护范围不受具体实施例的任何限制，而是由权利要求加以限定。
具体实施方式
实施例1 化合物闭花木酮Cleistanone的制备
化合物闭花木酮Cleistanone(I)的制备方法参照Van Trinh Thi Thanh等人发表的文献(Van Trinh Thi Thanh et al.,2011.Cleistanone:A Triterpenoid fromCleistanthus indochinensis with a New Carbon Skeleton.Volume 2011,Issue 22,pages 4108–4111,August 2011)的方法。
实施例2 闭花木酮Cleistanone的O-溴乙基衍生物(II)的合成
将化合物I(440mg，1.00mmol)溶于10mL苯，向溶液中加入四丁基溴化铵(TBAB)(0.04g)，1,2-二溴乙烷(3.760g，20.00mmol)和6mL的50％氢氧化钠溶液。混合物在25摄氏度搅拌24h。24h之后将反应液倒入冰水中，立即用二氯甲烷萃取两次，合并有机相溶液。然后对有机相溶液依次用水和饱和食盐水洗涤3次，再用无水硫酸钠干燥，最后减压浓缩去除溶剂得到产物粗品。产物粗品用硅胶柱层析纯化(流动相为：石油醚/丙酮＝100:1，v/v)，收集黄色集中洗脱带即得到化合物II的黄色固体(344mg，63％)。
1H NMR(500MHz,DMSO-d6)δ5.04(s,1H),4.82(s,1H),3.94(d,J＝26.5Hz,1H),3.87(d,J＝26.5Hz,2H),3.57(s,2H),2.40(d,J＝14.0Hz,1H),2.39(d,J＝14.0Hz,1H),2.27(s,1H),2.21(s,1H),2.15(s,1H),1.82(s,1H),1.62(s,2H),1.57(d,J＝3.3Hz,1H),1.54(d,J＝3.3Hz,1H),1.50(d,J＝1.2Hz,1H),1.47(d,J＝1.2Hz,1H),1.39(d,J＝15.3Hz,2H),1.34(d,J＝15.3Hz,1H),1.26(dd,J＝32.6,13.7Hz,4H),1.13(d,J＝18.0Hz,2H),1.05(s,6H),0.98(s,1H),0.88(s,12H),0.78(s,3H),0.74(s,1H)。
13C NMR(125MHz,DMSO-d6)δ216.59(s),154.50(s),105.23(s),74.63(s),69.85(s),59.71(s),52.55(s),51.21(s),47.92(s),44.10(s),42.25(s),41.73(s),40.64(s),40.16(s),38.88(s),38.65(s),37.21(s),36.23(s),33.34(d,J＝1.1Hz),32.96(s),29.91(s),27.18(s),26.03(s),24.23(s),23.96(s),20.77(s),18.48(s),17.98(s),16.93(s)。
HRMS(ESI)m/z[M+H]+calcd for C32H52BrO2:547.3151；found 547.3159.
实施例3 闭花木酮Cleistanone的O-(四氢吡咯基)乙基衍生物(III)的合成
将化合物II(273mg，0.5mmol)溶于20mL乙腈当中，向其中加入无水碳酸钾(345mg，2.5mmol)，碘化钾(84mg，0.5mmol)和吡咯烷(1420mg，20mmol)，混合物加热回流8h。反应结束后将反应液倒入冰水中，用等量二氯甲烷萃取三次，合并有机相。依次用水和饱和食盐水洗涤合并之后的有机相，再用无水硫酸钠干燥，减压浓缩去除溶剂得到产物粗品。产物粗品用硅胶柱层析纯化(流动相为：石油醚/丙酮＝100:1，v/v)，收集淡黄色集中洗脱带即得到Cleistanone的O-(四氢吡咯基)乙基衍生物的淡黄色胶状固体(185.3mg,69％)。
1H NMR(500MHz,DMSO-d6)δ5.08(s,1H),4.89(s,1H),4.43(s,1H),3.59(s,2H),2.62(s,2H),2.58(s,4H),2.49(s,1H),2.44(s,1H),2.35(s,1H),2.25(s,1H),2.22(s,1H),1.88(s,1H),1.85–1.63(m,6H),1.61–1.52(m,4H),1.44(d,J＝13.7Hz,3H),1.32(dd,J＝19.4,11.7Hz,4H),1.21(d,J＝1.1Hz,2H),1.11(s,6H),0.95(s,1H),0.93(s,12H),0.86–0.78(m,4H).
13C NMR(125MHz,DMSO-d6)δ216.53(s),154.42(s),105.13(s),74.59(s),66.74(s),59.64(s),55.67(s),54.13(s),52.47(s),50.14(s),47.83(s),45.04(s),43.22(s),41.70(s),40.56(s),40.09(s),39.79(s),38.60(s),37.16(s),36.21(s),34.27(s),32.87(s),28.83(s),27.13(s),25.13(s),24.83(s),24.19(s),23.95(s),20.70(s),18.39(s),17.92(s),14.87(s).
HRMS(ESI):m/z[M+H]+calcd for C36H60NO2:538.4624；found:538.4628。
实施例4 Cleistanone的O-(四氢吡咯基)乙基衍生物抗胰腺纤维化活性
1材料
1.1动物Wistar大鼠，雄性，体重180-200g。
1.2Cleistanone的O-(四氢吡咯基)乙基衍生物剂量：0.9mg/kg。
2实验方法
2.1造模方法：Wistar大鼠以腹腔注射dl-乙硫氨酸250mg/天，连续2个月，可出现胰脏腺细胞减少，间质内脂肪及结缔组织的增生。
2.2分组及给药方法
模型大鼠随机分为模型组，Cleistanone的O-(四氢吡咯基)乙基衍生物0.9mg/kg组，另设空白对照组，于造模开始后给药，口服连续30天；60天时解剖动物。
2.3检测指标
2.3.1实验结束时取胰脏称重，计算脏器系数。
2.3.2胰脏羟脯氨酸含量测定取100mg样本在水中匀浆，110℃10N HCl中水解20小时。HCl用氮气挥发，水解产物用双蒸水溶解后过滤。取0.5ml液体与3ml枸橼酸磷酸缓冲液(0.15M枸橼酸加0.6M磷酸氢二钠)和0.5ml溶于9M磷酸的1M过碘酸混合。加1.75ml提取缓冲液(5份甲苯：5份2-甲基-1-丙醇：2份1-丙醇)，震荡30min，离心。组织相(0.6ml)与Ehrlich,s试剂混合放置15min。在565nm测定吸收度，用4-羟-1-脯氨酸制作标准曲线计算浓度，含量以ug/g组织表示。
2.3.3组织学检查胰脏组织用10％福尔马林固定，石蜡包埋，染色后镜检。对纤维化情况评分(0-3分)。
3结果
3.1Cleistanone的O-(四氢吡咯基)乙基衍生物对大鼠胰脏脏器系数的影响
实验结束时，将大鼠处死、解剖，称量体重和胰脏重并计算其与体重的比值，结果见表1。Cleistanone的O-(四氢吡咯基)乙基衍生物对胰脏脏器系数的影响，与模型组比较有显著性差异。
表1
*表示p<0.05，与模型组比较
3.2胰脏羟脯氨酸含量测定
实验结束时，对各组大鼠进行肺部羟脯氨酸含量测定，结果如表2。Cleistanone的O-(四氢吡咯基)乙基衍生物对羟脯氨酸含量的影响，与模型组比较有显著性差异。
表2
*表示p<0.05，与模型组比较
3.3组织学检查
实验结束时，将大鼠处死、解剖；标本常规包埋、固定、HE染色，镜检。
结果：模型组第60天可见胰导管周围严重炎症反应；嗜中粒细胞核淋巴细胞浸润，间质水肿，出血以及偶见胰泡细胞坏死；胰泡细胞消失位置及胰泡间出现纤维化。
Cleistanone的O-(四氢吡咯基)乙基衍生物可减少炎症反应和纤维化。评分结果见表3。Cleistanone的O-(四氢吡咯基)乙基衍生物对评分的影响，与模型组比较有显著性差异。
表3
*表示p<0.05，与模型组比较；空白对照组的炎症细胞浸润和纤维化评分都为0.
结论：本发明通过Cleistanone的O-(四氢吡咯基)乙基衍生物对大鼠胰腺纤维化的影响，证实了Cleistanone的O-(四氢吡咯基)乙基衍生物具有抗胰腺纤维化的作用。因此，Cleistanone的O-(四氢吡咯基)乙基衍生物可作为活性成分用于制备抗胰腺纤维化的药物。
实施例5 本发明所涉及Cleistanone的O-(四氢吡咯基)乙基衍生物片剂的制备
取20克Cleistanone的O-(四氢吡咯基)乙基衍生物或者其药学上可接受的盐当中的一种，加入制备片剂的常规辅料180克，混匀，常规压片机制成1000片。
实施例6 本发明所涉及Cleistanone的O-(四氢吡咯基)乙基衍生物胶囊的制备
取20克Cleistanone的O-(四氢吡咯基)乙基衍生物或者其药学上可接受的盐当中的一种，加入制备胶囊剂的常规辅料如淀粉180克，混匀，装胶囊制成1000粒。
Claims (4)
1.一种具有式III所示结构的闭花木酮Cleistanone的O-(四氢吡咯基)乙基衍生物及其药学上可接受的盐在制备治疗胰腺纤维化药物中的应用，
2.如权利要求1所述的闭花木酮Cleistanone的O-(四氢吡咯基)乙基衍生物及其药学上可接受的盐在制备治疗胰腺纤维化药物中的应用，其特征为：所述闭花木酮Cleistanone的O-(四氢吡咯基)乙基衍生物及其药学上可接受的盐逆转胰腺纤维化所引起的胰脏脏器系数下降。
3.如权利要求1所述的闭花木酮Cleistanone的O-(四氢吡咯基)乙基衍生物及其药学上可接受的盐在制备治疗胰腺纤维化药物中的应用，其特征为：所述闭花木酮Cleistanone的O-(四氢吡咯基)乙基衍生物及其药学上可接受的盐逆转胰腺纤维化所引起的羟脯氨酸含量升高。
4.如权利要求1所述的闭花木酮Cleistanone的O-(四氢吡咯基)乙基衍生物及其药学上可接受的盐在制备治疗胰腺纤维化药物中的应用，其特征为：所述闭花木酮Cleistanone的O-(四氢吡咯基)乙基衍生物及其药学上可接受的盐逆转胰腺纤维化所引起的炎症细胞浸润升高。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410375246.7A CN104147019B (zh) | 2014-07-31 | 2014-07-31 | 闭花木酮的o-(四氢吡咯基)乙基衍生物在制备预防或治疗胰腺纤维化药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410375246.7A CN104147019B (zh) | 2014-07-31 | 2014-07-31 | 闭花木酮的o-(四氢吡咯基)乙基衍生物在制备预防或治疗胰腺纤维化药物中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104147019A CN104147019A (zh) | 2014-11-19 |
| CN104147019B true CN104147019B (zh) | 2016-08-24 |
Family
ID=51872784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410375246.7A Active CN104147019B (zh) | 2014-07-31 | 2014-07-31 | 闭花木酮的o-(四氢吡咯基)乙基衍生物在制备预防或治疗胰腺纤维化药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104147019B (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104758298A (zh) * | 2015-04-15 | 2015-07-08 | 南京大学 | 闭花木酮的o-(1h-四氮唑基)乙基衍生物在制备治疗或预防肾纤维化药物中的应用 |
| CN104739846A (zh) * | 2015-04-15 | 2015-07-01 | 南京大学 | 闭花木酮的o-(1h-四氮唑基)乙基衍生物在制备预防或治疗胰腺纤维化药物中的应用 |
| CN104825466A (zh) * | 2015-04-29 | 2015-08-12 | 南京广康协生物医药技术有限公司 | 闭花木酮的o-(苯并咪唑基)乙基衍生物在制备预防或治疗胰腺纤维化药物中的应用 |
| CN104800213A (zh) * | 2015-05-12 | 2015-07-29 | 南京大学 | Daphmalenine A衍生物在制备预防或治疗胰腺纤维化药物中的应用 |
| CN104922122A (zh) * | 2015-05-27 | 2015-09-23 | 南京广康协生物医药技术有限公司 | Daphmalenine A的O-(二乙胺基)乙基衍生物在制备预防或治疗胰腺纤维化药物中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102000086A (zh) * | 2006-03-06 | 2011-04-06 | 上海医药工业研究院 | 积雪酸在制备预防或治疗胰腺纤维化的药物中的应用 |
-
2014
- 2014-07-31 CN CN201410375246.7A patent/CN104147019B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104147019A (zh) | 2014-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104147019B (zh) | 闭花木酮的o-(四氢吡咯基)乙基衍生物在制备预防或治疗胰腺纤维化药物中的应用 | |
| CN104188978B (zh) | 闭花木酮的o-(四氢吡咯基)乙基衍生物在制备治疗或预防肾纤维化药物中的应用 | |
| CN104825466A (zh) | 闭花木酮的o-(苯并咪唑基)乙基衍生物在制备预防或治疗胰腺纤维化药物中的应用 | |
| CN104188980B (zh) | 闭花木酮Cleistanone的O-(吗啉基)乙基衍生物、制备方法及其用途 | |
| CN101665489B (zh) | 一类脱氢水飞蓟宾三烷基醚及其制备方法和药物用途 | |
| CN101565419B (zh) | 7及20位脱氢水飞蓟宾双烷醚及其制备方法和药物用途 | |
| CN104739846A (zh) | 闭花木酮的o-(1h-四氮唑基)乙基衍生物在制备预防或治疗胰腺纤维化药物中的应用 | |
| CN104095856B (zh) | 闭花木酮Cleistanone的二乙胺衍生物在制备抗急性肾衰药物中的应用 | |
| CN105193791A (zh) | 组合物及其在预防或治疗胰腺纤维化药物中的应用 | |
| CN105998003A (zh) | Salviskinone A的苯并咪唑基和二(2-甲硫基乙基)胺基衍生物的组合物在预防或治疗胰腺纤维化药物中的应用 | |
| CN105232508A (zh) | 一种组合物及其在预防或治疗胰腺纤维化药物中的应用 | |
| CN106074529A (zh) | 阿掏比克酸三唑基与1h‑四氮唑基衍生物的组合物用于制备防治胰腺纤维化药物 | |
| CN105878252A (zh) | Virosaine A的四氢吡咯基和吗啉基衍生物的组合物在预防或治疗胰腺纤维化药物中的应用 | |
| CN106038553A (zh) | SChiglautone A衍生物的组合物用于制备防治胰腺纤维化药物 | |
| CN106176733A (zh) | Schiglautone A的衍生物组合物在预防或治疗胰腺纤维化药物中的应用 | |
| CN106074480A (zh) | Artalbic acid的衍生物的组合物用于制备防治胰腺纤维化药物 | |
| CN106074516A (zh) | 阿掏比克酸苯并咪唑基与二羟乙胺基衍生物的组合物用于制备防治胰腺纤维化药物 | |
| CN104922122A (zh) | Daphmalenine A的O-(二乙胺基)乙基衍生物在制备预防或治疗胰腺纤维化药物中的应用 | |
| CN104800213A (zh) | Daphmalenine A衍生物在制备预防或治疗胰腺纤维化药物中的应用 | |
| CN106420719A (zh) | Atropurpuran衍生物组合物在预防或治疗胰腺纤维化药物中的应用 | |
| CN105078984A (zh) | 组合物71083001030522及其在预防或治疗胰腺纤维化药物中的应用 | |
| CN106727522A (zh) | Atropurpuran的咪唑基和二氯乙胺基衍生物组合物用于防治胰腺纤维化 | |
| CN103393669B (zh) | Chukrasone B在制备预防胰腺纤维化的药物中的应用 | |
| CN106727465A (zh) | Atropurpuran的衍生物组合物用于防治胰腺纤维化 | |
| CN106420750A (zh) | Harrisotone A的O‑(二乙氨基)乙基衍生物和O‑(哌嗪基)乙基衍生物的组合物在预防或治疗胰腺纤维化药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Ji Changsheng Inventor after: Guo Guangming Inventor after: Ma Xiuyao Inventor before: Wu Junyi Inventor before: Huang Rong Inventor before: Wu Junhua |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160608 Address after: The first people's Hospital of Suzhou City, Anhui Province, Suzhou City, 246000 North Street Office of the Milky Way Yongqiao district road two Applicant after: Ma Xiuyao Address before: No. 163 Xianlin University City Xianlin Avenue in Qixia District of Nanjing City, Jiangsu province 210093 Applicant before: Nanjing University |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190521 Address after: 314100 First Floor 102 of Building C7, No. 555 Pioneer Road, Dayun Town, Jiashan County, Jiaxing City, Zhejiang Province (Residence Declaration) Patentee after: Zhejiang Jiasheng Biomedical Co., Ltd. Address before: 246000 Beiguan Street Office, Longqiao District, Suzhou City, Anhui Province Patentee before: Ma Xiuyao |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 314100 First Floor 102 of Building C7, No. 555 Pioneer Road, Dayun Town, Jiashan County, Jiaxing City, Zhejiang Province (Residence Declaration) Patentee after: Jiasheng biomedical (Jiaxing) Co., Ltd Address before: 314100 First Floor 102 of Building C7, No. 555 Pioneer Road, Dayun Town, Jiashan County, Jiaxing City, Zhejiang Province (Residence Declaration) Patentee before: Zhejiang Jiasheng Biomedical Co., Ltd. |